

Labcorp® Plasma Focus™

Genes and Relevant Therapies

Gene/Biomarker	Alterations	Drugs and/or Relevance to Treatment
NSCLC		
<i>ALK</i>	Translocations	Alectinib, brigatinib, ceritinib, crizotinib
<i>ALK</i>	Oncogenic mutations	Lorlatinib
<i>BRAF</i>	V600E	Dabrafenib + trametinib
<i>EGFR</i>	Exon 19 in-frame deletions, L858R	Afatinib, dacomitinib, erlotinib, erlotinib + ramucirumab, gefitinib, osimertinib
<i>EGFR</i>	Exon 20 in-frame insertions	Amivantamab, mobocertinib
<i>EGFR</i>	G719	Afatinib
<i>EGFR</i>	L861Q	Afatinib
<i>EGFR</i>	S768I	Afatinib
<i>EGFR</i>	T970M	Osimertinib
<i>ERBB2 (HER2)</i>	Mutations	Trastuzumab deruxtecan
<i>KRAS</i>	G12C	Sotorasib, adagrasib
<i>MET</i>	D1010, exon 14 deletion, exon 14 in-frame deletions, exon 14 splice mutations	Capmatinib, tepotinib
<i>RET</i>	Translocations	Pralsetinib, selpercatinib
<i>ROS1</i>	Translocations	Crizotinib, entrectinib
<i>NTRK1</i>	Translocations	Entrectinib, larotrectinib
<i>MSI-H</i>	N/A	Pembrolizumab
Colon Cancer		
<i>BRAF</i>	V600E	Encorafenib + cetuximab
<i>KRAS</i>	Wild type	Cetuximab, cetuximab + chemotherapy, panitumumab, panitumumab + chemotherapy
<i>NRAS</i>	Wild type	Panitumumab, panitumumab + chemotherapy
<i>NTRK1</i>	Translocations	Entrectinib, larotrectinib
<i>MSI-H</i>	N/A	Nivolumab, ipilimumab + nivolumab
<i>RET</i>	Translocations	Pralsetinib, selpercatinib
Breast Cancer		
<i>ERBB2 (HER2)</i>	Amplification	Ado-trastuzumab emtansine, lapatinib + capecitabine, lapatinib + letrozole, margetuximab + chemotherapy, neratinib, neratinib + capecitabine, trastuzumab + pertuzumab + chemotherapy, trastuzumab + tucatinib + capecitabine, trastuzumab deruxtecan, trastuzumab, trastuzumab + chemotherapy
<i>PIK3CA</i>	C420R and 10 other alterations	Alpelisib + fulvestrant
<i>BRCA1</i>	Mutations	Olaparib, talazoparib
<i>BRCA2</i>	Mutations	Olaparib, talazoparib
<i>NTRK1</i>	Fusion	Larotrectinib, entrectinib
<i>MSI-H</i>	N/A	Pembrolizumab, dostarlimab-gxly
<i>RET</i>	Translocations	Pralsetinib, selpercatinib

NOTE: National Comprehensive Cancer Network guidelines and OncoKB™ were used in the construction of this table. MSI-H, microsatellite instability-high; N/A, not applicable; NSCLC, non-small cell lung cancer.

Labcorp[®] Plasma Focus[™]

Genes and Relevant Therapies

Gene/Biomarker	Alterations	Drugs and/or Relevance to Treatment
Melanoma		
<i>BRAF</i>	V600E, V600K	Trametinib + dabrafenib, vemurafenib + cobimetinib, encorafenib + binimetinib
<i>NRAS</i>	Mutations	Binimetinib ± ribociclib
<i>KIT</i>	Mutations	Imatinib, sunitinib, nilotinib
<i>NTRK1</i>	Translocations	Larotrectinib, entrectinib
<i>ALK</i>	Translocations	Crizotinib, entrectinib
<i>ROS1</i>	Translocations	Crizotinib, entrectinib
MSI-H	N/A	Pembrolizumab
<i>RET</i>	Translocations	Pralsetinib, selpercatinib
Esophageal, Gastric, and Gastroesophageal Cancers		
<i>ERBB2 (HER2)</i>	Amplification	Pembrolizumab + trastuzumab + chemotherapy, trastuzumab + chemotherapy, trastuzumab deruxtecan
<i>NTRK1</i>	Translocations	Entrectinib, larotrectinib
MSI-H	N/A	Pembrolizumab
<i>RET</i>	Translocations	Pralsetinib, selpercatinib

NOTE: National Comprehensive Cancer Network guidelines and OncoKB[™] were used in the construction of this table.
MSI-H, microsatellite instability-high; N/A, not applicable; NSCLC, non-small cell lung cancer.

For more information about Labcorp Plasma Focus, visit oncology.labcorp.com/liquid-biopsy or contact your Labcorp Oncology sales representative.

